Suppr超能文献

建立于活体供肝肝移植术后小肝综合征处理的多学科专家共识:医学、影像学和外科学处理方法:ILTS-iLDLT-LTSI 共识会议指南。

Management of Established Small-for-size Syndrome in Post Living Donor Liver Transplantation: Medical, Radiological, and Surgical Interventions: Guidelines From the ILTS-iLDLT-LTSI Consensus Conference.

机构信息

Division of Abdominal Transplantation, Department of Surgery, Stanford University School of Medicine, Palo Alto, CA.

The Liver Unit, King's College Hospital, London, United Kingdom.

出版信息

Transplantation. 2023 Oct 1;107(10):2238-2246. doi: 10.1097/TP.0000000000004771. Epub 2023 Sep 25.

Abstract

Small-for-size syndrome (SFSS) following living donor liver transplantation is a complication that can lead to devastating outcomes such as prolonged poor graft function and possibly graft loss. Because of the concern about the syndrome, some transplants of mismatched grafts may not be performed. Portal hyperperfusion of a small graft and hyperdynamic splanchnic circulation are recognized as main pathogenic factors for the syndrome. Management of established SFSS is guided by the severity of the presentation with the initial focus on pharmacological therapy to modulate portal flow and provide supportive care to the patient with the goal of facilitating graft regeneration and recovery. When medical management fails or condition progresses with impending dysfunction or even liver failure, interventional radiology (IR) and/or surgical interventions to reduce portal overperfusion should be considered. Although most patients have good outcomes with medical, IR, and/or surgical management that allow graft regeneration, the risk of graft loss increases dramatically in the setting of bilirubin >10 mg/dL and INR>1.6 on postoperative day 7 or isolated bilirubin >20 mg/dL on postoperative day 14. Retransplantation should be considered based on the overall clinical situation and the above postoperative laboratory parameters. The following recommendations focus on medical and IR/surgical management of SFSS as well as considerations and timing of retransplantation when other therapies fail.

摘要

小肝综合征(SFSS)是活体肝移植后的一种并发症,可能导致严重后果,如移植物功能长期不良,甚至移植物丢失。由于对该综合征的担忧,一些不匹配供体的移植可能不会进行。小供体的门静脉高灌注和高动力内脏循环被认为是该综合征的主要发病机制。SFSS 的治疗主要取决于临床表现的严重程度,初始治疗重点是药物治疗以调节门静脉血流,并为患者提供支持性护理,以促进移植物再生和恢复。当药物治疗失败或病情进展,出现即将发生的功能障碍甚至肝功能衰竭时,应考虑介入放射学(IR)和/或手术干预以减少门静脉过度灌注。虽然大多数患者通过药物、IR 和/或手术治疗允许移植物再生,可获得良好的结局,但在术后第 7 天胆红素 >10mg/dL 和 INR>1.6 或术后第 14 天胆红素孤立性 >20mg/dL 的情况下,移植物丢失的风险会显著增加。应根据整体临床情况和上述术后实验室参数考虑再次移植。以下建议侧重于 SFSS 的药物和 IR/手术治疗,以及在其他治疗失败时再次移植的考虑因素和时机。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验